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Abstract 27 
Objective This study aimed to determine in obese women if endocannabinoid receptor 28 
antagonism has effects on fatty acid and triglyceride metabolism and insulin sensitivity which 29 
are independent from the metabolic effects of weight loss. 30 
Materials/Methods Fourteen obese (BMI=33.0±0.5 kg/m2) (mean ±SEM) Caucasian post-31 
menopausal women, aged 57.8±4.7 years were studied. The women were randomised to 2 32 
groups, one group received the endocannabinoid receptor antagonist rimonabant (20mg/d) for 33 
12 weeks. A control group achieved the same weight loss by a hypocaloric dietary 34 
intervention over 12 weeks. Palmitate production rate (Ra), a measure of lipolysis, and 35 
palmitate oxidation rate, and VLDL1 and VLDL2 triglyceride (TG) kinetics, were measured 36 
using isotopic tracers before and after the intervention.   37 
Results Weight loss was not different in the 2 groups; 2.6±0.5kg with rimonabant and 38 
3.1±1.0kg in the control group. Palmitate Ra increased with rimonabant with no change in the 39 
control group (p=0.03 between groups). Palmitate oxidation rate increased with rimonabant 40 
but decreased in the control group (p=0.005 between groups). VLDL1 TG secretion rate 41 
decreased in the control group and increased in the rimonabant group (p=0.008 between 42 
groups). There was no significant effect on insulin sensitivity. 43 
Conclusions This study suggests that endocannabinoid receptor antagonism for 12 weeks in 44 
obese women increased lipolysis and fatty acid oxidation. The increase in VLDL1 TG 45 
secretion rate may be due to the increase in lipolysis which exceeded the increase in fatty acid 46 
oxidation. 47 
 48 
Key words: Cannabinoid receptor-1 antagonist, Obese, fatty acid production rate, fatty acid 49 
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Abbreviations: FCR, fractional clearance rate; IHCL, intrahepatocellular lipid; IMCL, 52 
intramyocellular lipid; MCR metabolic clearance rate; Ox, oxidation rate; Ra, production 53 
rate; REE, resting energy expenditure; SR, secretion rate; TEE, total energy expenditure; TG, 54 
triglyceride; VLDL, very low density lipoprotein. 55 
56 
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Introduction 57 
The endocannabinoid system is involved in the physiological control of food intake and 58 
energy balance [1]. It is overactive in human obesity [2] and in diet-induced obese mice [3,4]. 59 
Mice with a genetic deletion in the CB1 cannabinoid receptor are leaner than their pair fed 60 
wild type littermates and when fed a high fat diet do not become obese or develop insulin 61 
resistance [5] suggesting they have increased energy expenditure. The CB1 antagonist 62 
rimonabant (SR141716) reduced food intake transiently in diet-induced obese mice, but a 63 
decrease in body weight was prolonged, also suggesting an effect on energy expenditure [6]. 64 
In ob/ob mice treated for 7 days with rimonabant, basal oxygen consumption increased 37% 65 
compared to control mice [7].  66 
 67 
Three studies in obese subjects (BMI 33-38 kg/m2) completing 12 months of treatment with 68 
rimonabant (20 mg/d) showed a mean weight loss from baseline of 8.5 kg, accompanied by a 69 
decrease in plasma TG and an increase in insulin sensitivity [8, 9,10]. Calculation of the 70 
expected metabolic effects of the body weight loss suggested that 50% of the improvements 71 
in TG and insulin sensitivity could not be attributed to weight loss per se [10]. 72 
 73 
Since weight loss can cause significant changes in metabolism, to determine the direct effects 74 
of rimonabant rather than those due to weight loss, this study compared changes in fatty acid 75 
and triglyceride metabolism in a rimonabant-treated group and a control group treated only 76 
with diet with weight loss matched for that achieved in the rimonabant group. To investigate 77 
whether rimonabant could induce weight loss due to effects on energy expenditure, energy 78 
intake was maintained at pre-treatment levels in the treatment group. 79 
80 
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Methods 81 
Study design 82 
This study was registered with ClinicalTrials.gov (NCT00584389) and approved by the UK 83 
Medicines and Healthcare Products Regulatory Agency (Eudract 2006-006424-18), the East 84 
Kent Ethics Committee and University of Surrey Ethics Committee. All subjects provided 85 
written informed consent. The study was powered for 30 obese (BMI 30-35 kg/m2) Caucasian 86 
post-menopausal women, randomised into two groups. The treatment group (n=15) was to 87 
receive rimonabant (20mg/d) for 12 weeks with energy intake matched to their energy 88 
requirements, determined during a 4 week run-in pre-treatment period.  The control group 89 
(n=15) was to follow a dietary intervention to achieve the same weight loss as the rimonabant 90 
group. Exclusion criteria are shown in the Supplement. The European Medicines Agency 91 
withdrew marketing authorisation for rimonabant in 2008, rimonabant was withdrawn from 92 
the market by the Sanofi-aventis, and the study was terminated. Studies had been completed in 93 
14 women randomised into the rimonabant (age 58.1±1.9y; BMI 32.9±0.7) and control group 94 
(age 57.4±1.9y; BMI 33.0±0.8) (n=7/group).  95 
 96 
After recruitment and randomisation, participants entered a 4 week run-in period (see 97 
Supplement). At the end of this period the following measurements were made; whole body 98 
fat by bioimpedance, resting energy expenditure (REE) by indirect calorimetry, insulin 99 
sensitivity with a euglycemic hyperinsulinemic clamp, palmitate Ra, Ox and metabolic 100 
clearance rate (MCR) with an infusion of 13C palmitate and 13C acetate, VLDL1 and VLDL2-101 
TG secretion and FCR, with an intravenous bolus of 2H5 glycerol and IHCL and IMCL by 102 
magnetic resonance spectroscopy (see Supplement). These measurements were repeated after 103 
12 weeks.  104 
 105 
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For laboratory methods and data analysis see the Supplement. 106 
 107 
Statistical analysis 108 
The results are presented as means ± SEM.  Within group changes were analysed by paired t 109 
test and changes between groups by t test using SPSS (version 16). Non parametric data was 110 
logarithmically transformed before analysis. 111 
112 
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Results 113 
During the run-in period TEE was not significantly different from energy intake confirming 114 
participants were not under-reporting energy intake. Reported energy intake was maintained 115 
with rimonabant for 13 weeks and decreased in controls (Table 1) (Figure 2, Supplement) due 116 
to a decrease in fat and carbohydrate intake (Table 2, Supplement). Weight loss, which was 117 
2.6±0.5kg with rimonabant (p<0.003), and 3.1±1.0kg in controls (p<0.03) was not different 118 
between groups. There was a similar reduction in waist circumference and fat mass but no 119 
change in IHCL and IMCL in both groups (Table 1, Supplement). REE tended to decrease in 120 
controls (p=0.055), as expected with weight loss but was maintained with rimonabant despite 121 
weight loss. Insulin sensitivity, increased in both groups but was not statistically significant 122 
(Table 1).  123 
 124 
The change in palmitate Ra over 12 weeks was significantly different between groups 125 
(p=0.03) with a within group increase (p<0.05) with rimonabant (Table 2).  Palmitate MCR 126 
also increased (p=0.05) with rimonabant. There was no change in these measurements in the 127 
control group. Palmitate Ox  increased with  rimonabant and decreased in controls with a 128 
difference between groups (p=0.005).  Palmitate Ra, and Ox were also different between 129 
groups when expressed per kg of fat free mass (p=0.03, p=0.01).When expressed per kg of fat 130 
mass palmitate Ra increased with rimonabant (p=0.02) and was different between groups 131 
(p=0.04). 132 
 133 
Plasma TG decreased in controls (p<0.05) but did not change with rimonabant (Table 1). 134 
VLDL1 TG concentration decreased in controls (p=0.07). VLDL1 SR increased with 135 
rimonabant and decreased in controls (p<0.008 between groups) (Table 2). 136 
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Discussion 137 
This study demonstrated that the CB1 receptor antagonist rimonabant had metabolic effects 138 
which were independent of weight loss. Using stable isotope techniques it was shown that 139 
palmitate Ra, a measure of lipolysis, and palmitate MCR increased after rimonabant 140 
treatment for 12 weeks. Palmitate Ox  also increased with rimonabant, in contrast to the 141 
controls where palmitate Ox decreased. VLDL TG kinetics were also different in the 2 142 
groups with an increase in VLDL1 TG SR with rimonabant but a decrease in the control 143 
group suggesting that the increased lipolysis with rimonabant treatment may have driven an 144 
increase in hepatic TG synthesis. REE decreased in the controls but did not decrease with 145 
rimonabant despite similar weight loss suggesting an effect on energy expenditure 146 
 147 
This is the first demonstration that palmitate oxidation is increased with a CB1 receptor 148 
antagonist in humans and importantly confirms previous animal studies. In rats fed a high fat 149 
diet, rimonabant treatment increased the oxygen consumption of liver mitochondria and 150 
increased fatty acid entry into liver mitochondria via CPT I [11]. Increased hepatic CPT1 151 
activity has also been reported in mice fed a high fat diet and treated with rimonabant [12].  152 
The peripheral CB1 receptor antagonist, AM6545 has also been shown to increase fat 153 
oxidation, in mice fed either a standard laboratory diet or a high fat diet [13]. 154 
 155 
This is also the first demonstration in humans that a CB1 receptor antagonist increases 156 
lipolysis. Adipocytes express CB1 receptors and endocannabinoids have been shown to 157 
inhibit lipolysis via inhibition of adenylate cyclase [14].  CB1 receptors are also present on 158 
peripheral sympathetic nerve terminals where they mediate inhibition of norepinephrine 159 
release [15]. Blockade of these receptors by rimonabant is another possible mechanism for 160 
the increase in lipolysis in adipose tissue which is highly innervated by the SNS.  161 
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 162 
The decrease in plasma TG in the controls was in VLDL1 due to a decrease in VLDL1 TG 163 
secretion. Previous studies have also shown weight loss due to caloric restriction to decrease 164 
VLDL TG secretion [16].  Despite similar weight loss with rimonabant VLDL1 TG secretion 165 
increased. Since the increase in palmitate Ra was greater than the increase in palmitate 166 
oxidation rate with rimonabant, VLDL1 secretion may have increased due to an increased 167 
delivery of fatty acids to the liver driving VLDL1 synthesis. This contrasts with the large 168 
rimonabant clinical trials in which plasma TG decreased after 52 weeks when weight was 169 
beginning to stabilize. After 12 weeks [8, 9,10], the rate of weight loss would be expected to 170 
be high. Treatment of both diet induced mice and ob/ob mice with the peripheral CB1 171 
receptor antagonist, AM6545 for 7 days was also shown to increase TG secretion [13].  172 
 173 
One aim of the study had been to investigate whether weight loss would occur due to 174 
increased energy expenditure if calorie intake could be maintained in the rimonabant group. 175 
The lack of a decrease in REE with rimonabant, despite weight loss, suggests there was an 176 
effect on energy expenditure. Strack et al (2011) also found total EE measured with double 177 
labelled water did not decrease following pharmacologic inhibition of the CB1 receptor in a 178 
canine model despite an 11% reduction in body weight, whereas total EE decreased in a food 179 
restricted control group with only 6% weight loss [17]. 180 
 181 
This is a small study, reduced in size due to the withdrawal of rimonabant during the trial and 182 
therefore may be limited by lack of power to detect some differences. Nevertheless the 183 
demonstration of metabolic changes in a small study shows the powerful effect of rimonabant 184 
on lipolysis and fatty acid oxidation in obese humans which could be detected using isotopic 185 
tracers. Further studies of the role of the endocannabinoid system in the control of fatty acid 186 
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metabolism and energy balance may lead to the development of anti-obesity drugs which do 187 
not have the unacceptable side effects of rimonabant. 188 
 189 
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Table 1. Energy balance, hormones, lipids and insulin sensitivity 273 
 Rimonabant Group 
 
Control Group 
 
∆ rimonabant 
vs  ∆ control 
Week 0 Week 12 Week 0 Week 12 
Energy intake 
(kcal/day) 
1991±99 1963±73 1906±36 1564±56* P=0.002 
REE (kcal/day)  1434±59 1436±50 1453±76 1386±76‡ NS 
Glucose (mmol/l) 5.6±0.2 5.4±0.1 5.4±0.2 5.4±0.2 NS 
GIR/I (µg/kg/min/ 
[pmol/l]) 
5.07±1.09 6.04±1.41 5.80±1.12 6.06±1.07 NS 
Triglyceride                   
(mmol/l)  
1.6±0.6 1.7±0.5 1.2±0.1 0.9±0.1† NS 
Cholesterol 
(mmol/l)      
5.6±0.5 5.4±0.7 5.3±0.4 5.0±0.5 NS 
HDL-Cholesterol 
(mmol/l) 
1.39±0.13 1.49±0.13‡ 1.32±0.05 1.55±0.07* NS 
Adiponectin 
(µg/ml) 
12.0±1.4 11.9±1.5 11.3±1.7 10.8±1.8† NS 
Leptin ng/ml 23.5±2.9 20.6±3.0* 19.5±1.5 16.8±1.7* NS 
GIR/I, glucose infusion rate /Insulin. Significantly different from run-in period, 274 
†p<0.05; *, p<0.01; ‡, p=0.05275 
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Table 2. Palmitate and VLDL kinetics 276 
 Rimonabant Group 
 
Control Group 
 
∆ rimonabant 
vs ∆ control 
Week 0 Week 12 Week 0 Week 12 
FFA mmol/l 0.84±0.09 0.83±0.06 0.80±0.09 0.81±0.08 NS 
Glycerol µmol/l 147±15 124±17 141±15 145±12 NS 
Palmitate µmol/l 152±13 157±13 139±10 140±18 NS 
Palmitate Ra 
µmol/min 
189±6 229±17† 208±24 189±18 P=0.03 
Palmitate MCR 
ml/min 
1286±104 1541±146* 1500±158 1467±185 NS 
Palmitate ox 
µmol/min 
64±4 81±6* 77±8 65±4‡ P=0.005 
VLDL1 TG mmol/l 1.01±0.39 1.16±0.32 0.64±0.04 0.48±0.06§ P=0.03 
VLDL2 TG mmol/l 0.26±0.07 0.30±0.06 0.18±0.03 0.17±0.03 NS 
VLDL1 TG FCR 
pools/d 
14.6±2.1 16.2±3.4 12.8±1.4 14.0±2.3 NS 
VLDL2 TG FCR 
pools/day 
13.4±1.4 13.5±3.0 14.6±1.7 17.7±2.9 NS 
VLDL1 TG SR g/d 25.8±4.5 36.7±8.9‡ 19.5±2.3 14.6±2.0§ P<0.008 
VLDL2 TG SR g/d 8.0±1.6 9.2±1.6 6.3±1.3 6.6±1.2 NS 
SR, secretion rate; FCR, fractional catabolic rate; MCR, metabolic clearance rate; ox, 277 
oxidation rate Ra, rate of appearance. n=6 for palmitate kinetics in the rimonabant 278 
group due to compromised venous access during the palmitate tracer infusion in 1 279 
subject; significantly different from 0 weeks, † p<0.05, * p=0.05, ‡ p=0.06, § p=0.07 280 
